The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2).

Vaccine 40

Vaccine Trials FDA Clinical Trials 40

The Pharma Data

MAY 15, 2023

The vaccine candidate demonstrated non-inferiority in primary endpoints for five Neisseria meningitidis serogroups (A, B, C, W, and Y) compared to two doses of Bexsero (meningococcal group B vaccine) and one dose of Menveo (meningococcal group A, C, W-135, and Y conjugate vaccine) in 10–25-year-olds.

Vaccine 40

Vaccine Immune Response Licensing Licensing 40

Drug Target Review

DECEMBER 28, 2023

These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response. Neoantigens are recognised as non-self and trigger an immune response. To fell the entire tree, it is necessary to target the original clonal neoantigens that are present in every cancer cell.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

The Pharma Data

JANUARY 11, 2021

Xiaomin Fan, Founder, President and CEO of AvantGen, “Even with the recent Emergency Use Authorization of multiple vaccines, we believe there remains an urgent need for potent antibody therapies and prophylactics for immunocompromised patients who cannot mount an adequate immune response either to the vaccine or to subsequent viral infection.

Licensing 52

Licensing Licensing Therapies Engineering 52

Codon

DECEMBER 12, 2024

In 2010, researchers at the J. Similarly, about 40 percent of people with a deficiency in either IRAK-4 or MyD88 — key signaling molecules just downstream of the pattern recognition receptors — die before reaching adulthood, despite receiving vaccines, antibiotics, and advanced medical treatment.

DNA 104

DNA RNA Vaccine Virus 104

Codon

JANUARY 26, 2025

Once they identified the cause, scientists in New York City and elsewhere hurried to create a vaccine. American researchers tested the first flu vaccines on military personnel in the early 1940s, with a civilian rollout following in 1945. Receiving the seasonal vaccine reduces the risk of infection by just 40 percent on average.

Vaccine 105

Vaccine Immune Response Virus Clinical Trials 105